HIV/AIDS

Showing 12 posts of 12 posts found.

Gilead’s HIV treatment meets primary trial endpoint

December 16, 2025
Research and Development Gilead, HIV/AIDS

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

November 27, 2025
Product launch Gilead, HIV/AIDS

Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and Zambia, a milestone in the …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

European Commission approves HIV prevention injection

August 28, 2025
Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …

Takeda announces launch of Framework to help support patient access to life-extending combination treatments

February 25, 2025
Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access

The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …

HIV vaccine candidate successfully optimised for industrial production

October 30, 2024
Research and Development HIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement

Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise …

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024
Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

February 21, 2024
Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

The Gateway to Local Adoption Series

Latest content